Get the Stockscreener App
77.74
10.61%
7.46
After Hours:
77.00
-0.74
-0.95%
Mirum Pharmaceuticals Inc stock is traded at $77.74, with a volume of 3.83M.
It is up +10.61% in the last 24 hours and up +10.37% over the past month.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.
See More
Previous Close:
$70.28
Open:
$71.06
24h Volume:
3.83M
Relative Volume:
5.30
Market Cap:
$4.02B
Revenue:
$379.25M
Net Income/Loss:
$-77.34M
P/E Ratio:
-48.22
EPS:
-1.6122
Net Cash Flow:
$-27.87M
1W Performance:
+19.60%
1M Performance:
+10.37%
6M Performance:
+53.03%
1Y Performance:
+89.01%
1-Day Range:
$70.76
$79.95
1-Week Range:
$63.23
$79.95
52-Week Range:
$36.88
$79.95
Mirum Pharmaceuticals Inc Stock (MIRM) Company Profile
Name
Mirum Pharmaceuticals Inc
Sector
Industry
Phone
650-667-4085
Address
989 EAST HILLSDALE BOULEVARD, SUITE 300, FOSTER CITY
Compare MIRM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MIRM
Mirum Pharmaceuticals Inc
|
77.74 | 3.63B | 379.25M | -77.34M | -27.87M | -1.6122 |
|
VRTX
Vertex Pharmaceuticals Inc
|
456.20 | 113.51B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
767.96 | 78.69B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.23 | 52.32B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
854.99 | 52.15B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
174.84 | 35.52B | 447.02M | -1.18B | -906.14M | -6.1812 |
Mirum Pharmaceuticals Inc Stock (MIRM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-24-25 | Initiated | TD Cowen | Buy |
| Aug-11-25 | Resumed | Stifel | Buy |
| May-19-25 | Resumed | H.C. Wainwright | Buy |
| Apr-17-24 | Initiated | Stifel | Buy |
| Dec-18-23 | Reiterated | H.C. Wainwright | Buy |
| Nov-20-23 | Resumed | JP Morgan | Overweight |
| Nov-13-23 | Initiated | Morgan Stanley | Overweight |
| Oct-24-23 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-17-23 | Resumed | Evercore ISI | Outperform |
| Sep-20-23 | Initiated | JMP Securities | Mkt Outperform |
| Sep-01-22 | Initiated | Citigroup | Buy |
| Sep-20-21 | Initiated | JP Morgan | Overweight |
| Aug-07-20 | Upgrade | Raymond James | Outperform → Strong Buy |
| Aug-03-20 | Initiated | H.C. Wainwright | Buy |
| Jul-31-20 | Initiated | Piper Sandler | Overweight |
| Jun-25-20 | Initiated | Robert W. Baird | Outperform |
| Aug-12-19 | Initiated | Citigroup | Buy |
| Aug-12-19 | Initiated | Evercore ISI | Outperform |
| Aug-12-19 | Initiated | Guggenheim | Buy |
| Aug-12-19 | Initiated | ROTH Capital | Buy |
| Aug-12-19 | Initiated | Raymond James | Outperform |
View All
Mirum Pharmaceuticals Inc Stock (MIRM) Latest News
Will Mirum Pharmaceuticals Inc. stock pay special dividends2025 Macro Impact & Risk Adjusted Buy and Sell Alerts - ulpravda.ru
How Mirum Pharmaceuticals Inc. stock compares to growth peersMarket Growth Summary & Low Drawdown Momentum Trade Ideas - ulpravda.ru
Mirum Pharmaceuticals Surges Following Strategic Moves and Analyst Ratings - timothysykes.com
Is Mirum Pharmaceuticals Inc. stock supported by strong fundamentalsM&A Rumor & High Accuracy Trade Signal Alerts - ulpravda.ru
Mirum Pharmaceuticals files patent suits to block generic Livmarli approval By Investing.com - Investing.com Nigeria
Mirum Pharmaceuticals files patent suits to block generic Livmarli approval - Investing.com
Mirum Pharmaceuticals: Bluejay Acquisition Boost - StocksToTrade
Mirum Files Patent Suits to Block Livmarli Generics - TipRanks
Mirum secures $68.5 million in private placement ahead of acquisition By Investing.com - Investing.com Nigeria
Mirum Pharmaceuticals stock hits all-time high at 78.55 USD - Investing.com
Mirum Pharmaceuticals (MIRM) Stock Jumps on New $68.5M TCGX Financing, Bluejay Deal Momentum, and a Fresh $140 Price Target - ts2.tech
Mirum Pharmaceuticals (NASDAQ:MIRM) Trading Up 8.9% Following Analyst Upgrade - MarketBeat
Mirum Pharmaceuticals Announces Additional Private Placement Financing With TCGX - Investing News Network
Mirum Pharmaceuticals to raise $68.5M in private placement with TCGX - MSN
Mirum Pharmaceuticals announces additional private placement financing with TCGX - marketscreener.com
Mirum secures $68.5 million in private placement ahead of acquisition - Investing.com
Mirum Pharmaceuticals (NASDAQ:MIRM) Price Target Raised to $140.00 - MarketBeat
Mirum Pharmaceuticals Signs Multiple Material Agreements - TradingView — Track All Markets
Can Mirum Pharmaceuticals Inc. stock reach $100 price target2025 Investor Takeaways & Verified Momentum Stock Ideas - DonanımHaber
Mirum Pharmaceuticals stock price target raised to $140 by Citizens - Investing.com Canada
Citizens raises Mirum Pharmaceuticals stock price target to $140 on pipeline confidence - Investing.com Canada
Market Recap: Can Mirum Pharmaceuticals Inc. stock maintain growth trajectoryTrade Risk Report & Weekly Hot Stock Watchlists - ulpravda.ru
Is Mirum Pharmaceuticals Inc. stock trading at a premium valuationJuly 2025 Patterns & Advanced Swing Trade Entry Alerts - ulpravda.ru
What hedge fund activity signals for Mirum Pharmaceuticals Inc. stockQuarterly Profit Summary & Low Risk Entry Point Guides - ulpravda.ru
Will Strong Livmarli Uptake Continue to Aid MIRM's Revenues in 2026? - Yahoo Finance
Can Mirum Pharmaceuticals Inc. stock maintain growth trajectoryGold Moves & Free Fast Gain Swing Trade Alerts - Улправда
Stifel Nicolaus Issues Positive Forecast for Mirum Pharmaceuticals (NASDAQ:MIRM) Stock Price - MarketBeat
Why Mirum Pharmaceuticals Stock is Climbing - TipRanks
Baird lifts Mirum Pharmaceuticals, Inc. (MIRM) price target on Bluejay Therapeutics acquisition - MSN
The week in pharma: action, reaction and insight – week to December 12 - The Pharma Letter
Eventide Asset Management LLC Has $134.22 Million Holdings in Mirum Pharmaceuticals, Inc. $MIRM - MarketBeat
Mirum Pharmaceuticals, Inc. $MIRM Shares Sold by BVF Inc. IL - MarketBeat
Boone Capital Management LLC Has $32.64 Million Stock Position in Mirum Pharmaceuticals, Inc. $MIRM - MarketBeat
MIRM's Q3 Earnings & Revenues Beat Estimates, 2025 View Tightened - MSN
Rx Rundown: Pfizer, Mirum Pharmaceuticals, Novartis and more - Medical Marketing and Media
Mirum Pharmaceuticals stock price target raised to $110 by Raymond James - Investing.com Canada
Baird Lifts Mirum Pharmaceuticals, Inc. (MIRM) Price Target on Bluejay Therapeutics Acquisition - Insider Monkey
Morgan Stanley Raises Mirum (MIRM) PT to $95 on Strategic Bluejay Acquisition, Brelovitug Pipeline Addition - Insider Monkey
What is HC Wainwright's Forecast for MIRM FY2025 Earnings? - MarketBeat
Mirum Stock Slips On $820M Bluejay Deal — But Wall Street Calls The Hepatitis Drug Seal A 'Steal' - MSN
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)December 10, 2025 - BioSpace
Mirum Pharmaceuticals (MIRM): Assessing Valuation After Strong Long-Term Returns and Recent Share Price Pullback - Yahoo Finance
Mirum expands into liver diseases with Bluejay Therapeutics acquisition - MSN
Mirum Pharmaceuticals (Nasdaq: MIRM) approves stock option and RSU inducement grants for 8 new hires - Stock Titan
Mirum Pharmaceuticals stock price target raised to $100 by Leerink - Investing.com Canada
Trading Systems Reacting to (MIRM) Volatility - news.stocktradersdaily.com
Baird Maintains Mirum Pharmaceuticals (MIRM) Outperform Recommendation - Nasdaq
Mirum adds to liver disease pipeline with Bluejay takeout: Deals Report - biocentury.com
One Peninsula drug maker to buy another for up to $820 million around drug cut by Novartis - The Business Journals
Mirum Pharmaceuticals' Bluejay Acquisition Expands Liver Disease Pipeline, Morgan Stanley Says - marketscreener.com
Mirum Pharmaceuticals stock rises as H.C. Wainwright reiterates Buy rating By Investing.com - Investing.com Canada
Mirum Pharmaceuticals Inc Stock (MIRM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.44%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):